NASDAQ:NVIV InVivo Therapeutics - NVIV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding InVivo Therapeutics Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $2.20 -0.09 (-3.93%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.18▼$2.3650-Day Range$1.76▼$2.6352-Week Range$1.61▼$13.77Volume59,700 shsAverage Volume67,244 shsMarket Capitalization$4.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About InVivo Therapeutics (NASDAQ:NVIV) StockInvivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA.Read More Receive NVIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NVIV Stock News HeadlinesJanuary 11, 2023 | benzinga.comInVivo Therapeutics Hldg Stock (NASDAQ:NVIV), Quotes and News SummaryOctober 11, 2022 | finance.yahoo.comInVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq RulesJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.October 10, 2022 | marketwatch.comInVivo Therapeutics Shares Continue Friday's Fall, Hit All-Time Intraday LowOctober 7, 2022 | seekingalpha.comInVivo Therapeutics dips 24% on $9M direct and private placement offeringsOctober 7, 2022 | marketwatch.comInVivo Therapeutics Stock Drops on $9 Million OfferingOctober 7, 2022 | investorplace.comWhy Is InVivo Therapeutics (NVIV) Stock Down 34% Today?October 7, 2022 | finance.yahoo.comInVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq RulesJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.September 9, 2022 | finance.yahoo.comInVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment ConferenceAugust 28, 2022 | uk.finance.yahoo.comInVivo Therapeutics Holdings Corp. (NVIV)July 13, 2022 | finance.yahoo.comInVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General CounselJune 8, 2022 | finance.yahoo.comInVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed NeurosurgeryJune 2, 2022 | finance.yahoo.comInVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury StudyApril 18, 2022 | finance.yahoo.comWhy Are InVivo Therapeutics Shares Trading Lower During Premarket Monday?April 15, 2022 | nasdaq.comWhy InVivo Therapeutics Stock Falling?April 14, 2022 | marketwatch.comInVivo Therapeutics Announces 1-for-25 Reverse Stock SplitApril 14, 2022 | finance.yahoo.comInVivo Therapeutics stock sinks after 1-for-25 reverse stock split announcedApril 14, 2022 | seekingalpha.comInVivo Therapeutics slumps 7% on 1-for-25 reverse stock splitFebruary 8, 2022 | finanznachrichten.deSidekick Health: DTx leader Sidekick announces key C-level hires in move to accelerate U.S. market growthFebruary 8, 2022 | finance.yahoo.comDTx leader Sidekick announces key C-level hires in move to accelerate U.S. market growthJanuary 30, 2022 | fool.comInVivo Therapeutics Holdings(NVIV)January 6, 2022 | finance.yahoo.comInVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect ConferenceDecember 29, 2021 | nasdaq.comInVivo Therapeutics Holdings Corp Shares Fall 1.4% Below Previous 52-Week Low - Market MoverDecember 29, 2021 | nasdaq.comInVivo Therapeutics Holdings Corp Shares Close the Day 11.0% Lower - Daily WrapSeptember 9, 2021 | finance.yahoo.comInVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment ConferenceSeptember 8, 2021 | finance.yahoo.comInVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury StudySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NVIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NVIV Company Calendar Last Earnings11/07/2022Today1/27/2023Next Earnings (Estimated)3/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVIV CUSIPN/A CIK1292519 Webwww.invivotherapeutics.com Phone(617) 863-5500FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($8.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,900,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-78.11% Return on Assets-63.33% Debt Debt-to-Equity RatioN/A Current Ratio4.62 Quick Ratio4.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.22 per share Price / Book0.17Miscellaneous Outstanding Shares1,915,000Free Float1,903,000Market Cap$4.21 million OptionableNot Optionable Beta0.76 Key ExecutivesRichard ToselliPresident, Chief Executive Officer & DirectorRichard C. ChristopherChief Financial Officer & TreasurerHeather M. HamelChief Legal Officer & General CounselKey CompetitorsSintx TechnologiesNASDAQ:SINTRa Medical SystemsNYSE:RMEDAssureNASDAQ:IONMMotus GINASDAQ:MOTSINVO BioscienceNASDAQ:INVOView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCBought 27,667 shares on 11/15/2022Ownership: 2.241%Vanguard Group Inc.Bought 16,946 shares on 11/15/2022Ownership: 0.885%Two Sigma Investments LPBought 11,521 shares on 11/15/2022Ownership: 0.602%Two Sigma Advisers LPBought 10,468 shares on 11/15/2022Ownership: 0.547%Renaissance Technologies LLCBought 27,725 shares on 11/14/2022Ownership: 1.448%View All Institutional Transactions NVIV Stock - Frequently Asked Questions How have NVIV shares performed in 2023? InVivo Therapeutics' stock was trading at $2.35 at the start of the year. Since then, NVIV stock has decreased by 1.3% and is now trading at $2.32. View the best growth stocks for 2023 here. When is InVivo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023. View our NVIV earnings forecast. How were InVivo Therapeutics' earnings last quarter? InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) released its quarterly earnings results on Monday, November, 7th. The biotechnology company reported ($1.98) EPS for the quarter. When did InVivo Therapeutics' stock split? InVivo Therapeutics's stock reverse split on the morning of Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of InVivo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares Preferred and Income Securities ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), Apollo Investment (AINV), IVERIC bio (OPHT), OPKO Health (OPK) and Cardiff Oncology (TROV). What is InVivo Therapeutics' stock symbol? InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV." How do I buy shares of InVivo Therapeutics? Shares of NVIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is InVivo Therapeutics' stock price today? One share of NVIV stock can currently be purchased for approximately $2.32. How much money does InVivo Therapeutics make? InVivo Therapeutics (NASDAQ:NVIV) has a market capitalization of $4.44 million. The biotechnology company earns $-9,900,000.00 in net income (profit) each year or ($8.14) on an earnings per share basis. How can I contact InVivo Therapeutics? InVivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The official website for the company is www.invivotherapeutics.com. The biotechnology company can be reached via phone at (617) 863-5500 or via email at info@invivotherapeutics.com. This page (NASDAQ:NVIV) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.